SHame prOpensity in bOrderline Personality Disorder
Study of Shame Propensity as a Prognostic Factor of Suicidal Behaviors in Patients With Borderline Personality Disorder
University Hospital, Montpellier
688 participants
Sep 18, 2020
INTERVENTIONAL
Conditions
Summary
Borderline Personality Disorder (BPD) is a common psychiatric disorder occurring in 2 to 6% of the population. 70% of patients with BPD do at least one Suicide Attempt (SA) in their lives. It makes BPD the most related to SA condition. Negative interpersonal events are among the main stressor inducing a SA. Patients with BPD are characterized by emotional dysregulation, impulsivity (repeated parasuicidal and suicidal behaviors), and instability in interpersonal relationships. The feeling of shame related to this psychiatric disorder could be one of the causes of the high SA rate. In this study, patients with BPD will be follow-up during 5 years. The main objective is to study the propensity to feel shame as a predictor of SA. This include: * Study of shame propensity as a predictive factor of suicidal behavior - Identify homogeneous subgroups of patients with BPD based on SA, and overall functioning. * Identify biological markers predicting SA * Identify predictive and protective treatments (pharmacological and psychotherapeutic) for SA
Eligibility
Inclusion Criteria5
- To be over 18
- Clinical diagnosis of BPD using the SCID II (Structured Clinical Interview for DSM-IV-Text Reviewed Axis II Personality Disorders)
- Having signed the informed consent
- Able to understand the nature, the purpose and the methodology of the study
- Able to understand and perform the clinical evaluations
Exclusion Criteria4
- Deprived of liberty (by judicial or administrative decision)
- Protected by law (guardianship)
- Exclusion period in relation to another protocol
- Not affiliated to a social security scheme
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
During each visit, a clinical evaluation will be carried out, as well as the filling of hetero-questionnaires and self-questionnaires. Two biological collections will be made: one during the inclusion visit, and the other during the last visit, 5 years after inclusion.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03994510